Drug Profile
Montelukast oral film - IntelGenx
Alternative Names: INT 0043/2015; INT0043; Montelukast VersaFilm®Latest Information Update: 17 Nov 2023
Price :
$50
*
At a glance
- Originator IntelGenx Corp.
- Class Acetates; Anti-inflammatories; Antiasthmatics; Antidementias; Bronchodilators; Neuroprotectants; Nootropics; Quinolines; Small molecules
- Mechanism of Action Leukotriene D4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Alzheimer's disease
- No development reported Mild cognitive impairment
Most Recent Events
- 14 Nov 2023 The Swedish Medical Products Agency (“MPA”), the Swedish Ethical Review Authority, and the Regional Biobank Centre approves phase II MONTPARK clinical study of Montelukast versaFilm® in Parkinson’s Disease
- 14 Nov 2023 IntelGenx plans a phase II MONTPARK clinical trial for Parkinson’s Disease in Q1 of 2024
- 01 Aug 2023 IntelGenx completes enrolment in the phase-II BUENA trial for Alzheimer's disease (In the elderly, In adults) in Canada (PO) (NCT03402503)